PRAME and melanoma: What is more, chidamide could induce the expression of the leukemia-specific antigen PRAME (preferentially expressed antigen in melanoma) in both cell lines and leukemia blasts from patients, resulting in increased PRAME-specific and CTL-mediated cytotoxicity against leukemia in vitro (Yao et al., 2013).